A world where no life is lost to an untreatable infection – where technology, biology, and global collaboration unite to end the threat of antimicrobial resistance.
To unlock the full potential of phage therapy— by delivering fast, targeted, and accessible phage therapy through AI-powered platform.
Every minute, at least two people die from infections that no longer respond to antibiotics. AMR (Antimicrobial Resistance) is no longer a distant threat – it is here, and it is a growing concern. By 2050, over 10 million lives will be lost annually because of antibiotics that no longer work against treating infections, and countless more face treatment delays, prolonged hospital stays, and uncertainty. Behind each statistic is a patient, a family, and a clinician searching for answers.
At the heart of our work is a belief: no one should die because modern medicine wasn’t fast or precise enough. Infections can be treated.
We’ve built a next-generation platform to respond to this global crisis with urgency and innovation. Our platform delivers precision phage therapy. What sets us apart is speed, intelligence, and readiness. We are revolutionizing the way we fight infections, offering a lifeline where antibiotics fall short.
We’re a multidisciplinary team of biologists, machine learning engineers, data scientists, and innovators—united by a shared mission to deliver faster, targeted and accessible phage therapy solutions for multidrug-resistant infections.
Co-founder, CEO
Dr. José Luis Bila is the CEO and Co-founder of Precise Health. With experience across biotech, medtech, and pharma, he brings deep scientific expertise and a strong focus on commercial strategy. José leads the company’s vision, product development, and partnerships—driven not only by his professional background but also by personal loss in his family due to antibiotic resistance. His work is grounded in a commitment to accelerate access to life-saving, precision therapies where antibiotics fall short.
Project Coordinator
Dr. José Santos completed his PhD in Infection Biology and Microbiology at the Institut Pasteur in Paris. He did his postdoctoral work at the Biozentrum, in Basel, and at the University of Lausanne, where he focused on innate immune responses to bacterial pathogens. With deep expertise in Microbiology, Immunology, Infection Biology, and Biochemistry, he brings several years of R&D experience to the biotech space. At Precise Health, José coordinates scientific projects to drive the development of innovative phage therapy solutions to combat multidrug-resistant bacterial infections.
Machine Learning Engineer
Farzaneh Labbaf is a Machine Learning Engineer with a background in computational biology and software development. She applies machine learning models to complex biological and clinical datasets, supporting the development of Precise Health’s core technology. Her work bridges data science and life sciences to enable AI-driven solutions for phage therapy.
Lead Microbiologist
Dr. Yassine El Chazli is a microbiologist with a strong background in microbial ecology and host-microbe interactions. He earned his PhD from the University of Lausanne, where he focused on the metabolic interplay between beneficial gut bacteria and their hosts. At Precise Health, Yassine leads efforts in building Phage Banks and advancing the development of phage therapy, contributing to innovative, bacteriophage-targeted solutions for precision medicine.
Strategic Parnerships Manager
Bioinformatician
Wan-Ting Huang is a bioinformatician with a strong foundation in molecular biology, bioinformatics, and physiology. At Precise Health, she develops scalable, reproducible pipelines to support the matching and engineering platforms, leveraging expertise in multi-omics, microbial genomics, and whole-genome analysis. Her work bridges data science and biology to deliver actionable insights for clinicians.
Co-founder, CEO
Doctor of science
Doctor of science
Doctor of science
Doctor of science
Driven by a deep commitment to clinical innovation and scientific rigor, our advisors bring together expertise in genomics, diagnostics, and medical research. They guide the development of evidence-based solutions that ensure our platform delivers meaningful, accurate insights advancing the future of precision medicine.
Pharmaceutical veteran with over 40 years of experience in drug development, intellectual property, and biotech entrepreneurship.
Infectious disease specialist at CHUV (Lausanne, Switzerland) and expert in host–pathogen interactions. He provides clinical insight into AMR and phage therapy application.
Founder & CEO of Innovoskin, with expertise in skin biology, microbiology, and product testing in dermatological and wound-care applications.
Phage researcher at the University of Bern. Her research focuses on phage characterization, resistance mechanisms, and clinical implementation strategies.
